| Authors: |
Tison F; Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. francois.tison@chu-bordeaux.fr.; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. francois.tison@chu-bordeaux.fr.; Service de Neurologie, CHU de Bordeaux, Bordeaux, France. francois.tison@chu-bordeaux.fr.; NS-Park/FCRIN Network, UMS 015, Toulouse, France. francois.tison@chu-bordeaux.fr., Keywood C; Addex Pharma SA, Plan Les Ouates, Switzerland., Wakefield M; Addex Pharma SA, Plan Les Ouates, Switzerland., Durif F; NS-Park/FCRIN Network, UMS 015, Toulouse, France.; Neurology Service, A, Hôpital Gabriel Montpied, Clermont Ferrand, France., Corvol JC; NS-Park/FCRIN Network, UMS 015, Toulouse, France.; Sorbonne Universités and UPMC Univ Paris 06, INSERM UMRS-1127 and CIC-1422; CNRS UMR-7225; AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Paris, France., Eggert K; Universitätsklinikum Giessen und Marburg, Klinik für Neurologie, Marburg, Germany., Lew M; Department of Neurology USC/Keck School of Medicine, Los Angeles, California, USA., Isaacson S; Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA., Bezard E; Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France.; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France., Poli SM; Addex Pharma SA, Plan Les Ouates, Switzerland., Goetz CG; Rush University Medical Center, Dept. of Neurological Sciences, Movement Disorder Section, Chicago, Illinois, USA., Trenkwalder C; Paracelsus Elena Klinik, centre for Parkinson's Disease & Movement Disorders, Kassel, Germany., Rascol O; NS-Park/FCRIN Network, UMS 015, Toulouse, France.; CIC9302, Departments of Clinical Pharmacology and Neurosciences and NeuroToul COEN Center; INSERM, University Hospital of Toulouse and University of Toulouse 3, Toulouse, France. |
